TY - CHAP M1 - Book, Section TI - Antimetabolites and Antimitotic Drugs in the Treatment of Keloid and Hypertrophic Scars A1 - Waldman, Abigail A1 - Alam, Murad A2 - Alam, Murad A2 - Dover, Jeffrey S. A2 - Waibel, Jill S. A2 - Arndt, Kenneth A. A2 - Kim, John Y. S. A2 - Thomas, J. Regan A2 - Gaball, Curtis W. A2 - Chan, Rodney K. Y1 - 2021 N1 - T2 - Treatment of Scars From Burns and Trauma AB - In addition to procedural interventions, and often in combination with these, antimetabolite and antimitotic drugs can be used to treat hypertrophic scars and keloids while also mitigating their likelihood of recurrence. Such drugs can be administered topically, intralesionally, or orally. Intralesional 5-fluorouracil, a pyrimidine analogue with antimetabolite activity that inhibits fibroblast proliferation, is the most common antimetabolite agent for thickened scars. Other options include oral methotrexate, an antimetabolite (antifolate) that prevents reduction of folate to its active form by inhibiting dihydrofolate reductase; intralesional bleomycin, a cytotoxic antibiotic derived from Streptomyces verticellus that has been shown to inhibit collagen synthesis and induce apoptosis; oral colchicine, an antimitotic agent believed to interfere with cell division through its disruptive action on the mitotic spindle, whereby it manifests a specific and dose-dependent inhibitory effect on collagen synthesis and fibroblast proliferation; and topical mitomycin C, a cytotoxic antineoplastic antibiotic produced by Streptomyces caespitosus, with antiproliferative effects on fibroblasts through DNA synthesis inhibition. Notably, virtually all of these scar reduction treatments, while evidence-based, are off-label indications for these drugs. SN - PB - McGraw Hill CY - New York, NY Y2 - 2024/04/25 UR - dermatology.mhmedical.com/content.aspx?aid=1176880336 ER -